Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




POC Oral Swab Test to Increase Chances of Pregnancy in IVF

By HospiMedica International staff writers
Posted on 13 May 2025

Approximately 15% of couples of reproductive age experience involuntary childlessness. More...

A significant reason for this is the growing trend of delaying family planning, a global shift that is expected to increase in the future. In vitro fertilization (IVF) treatment involves stimulating the woman’s ovaries to mature multiple eggs, which are then retrieved, fertilized with sperm in the lab, and later re-implanted into the uterus. There are two main types of hormone treatments available for egg maturation: biological and synthetic. However, while hormone therapy is essential, it carries risks of severe side effects, sometimes leading to the need for intensive care, and many IVF attempts are unsuccessful. One key factor influencing the success of IVF is the choice of hormone therapy, but healthcare providers often face the challenge of selecting the most effective treatment for each woman. Now, a simple oral swab test conducted before IVF could ensure higher success rates.

To identify the most effective hormone treatment for each individual, researchers at Lund University (Lund, Sweden) turned to genetics. Their study involved 1,466 women undergoing IVF treatment, excluding those with endometriosis or polycystic ovary syndrome (PCOS). Among the participants, 475 were randomly assigned to receive one of two hormone treatments, while the remaining participants served as controls. The researchers focused on a gene involved in fertilization, which regulates the action of follicle-stimulating hormone (FSH), a crucial hormone for egg maturation, and mapped this gene through gene sequencing.

The findings, published in Frontiers in Endocrinology, revealed that women carrying a specific variant of the FSH receptor (FSHR) gene, which regulates FSH activity, responded more favorably to biological hormone treatment. Meanwhile, other women benefited more from synthetic hormone treatments. The researchers believe that by understanding a woman’s genetic profile in advance, the likelihood of successful pregnancies can be significantly increased. However, gene mapping is both expensive and time-consuming. To address this, the researchers have developed a simple oral swab test that can quickly determine the most suitable hormone therapy within an hour, with the results indicated by a color change to pink or yellow, making it easy to interpret.

“Our hope is that this will reduce the risk of suffering for women, increase the number of successful treatments and cut costs for taxpayers. Our goal is for the test to be available by the start of 2026,” said Yvonne Lundberg Giwercman, professor at Lund University who led the research.


Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Surgical Headlight
IsoTorch
Radiation Safety Barrier
RayShield Intensi-Barrier
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.